Danaher Corporation ($DHR) Stock Forecast: Down 5.8% Today

What is Danaher Corporation?

Danaher Corporation (NYSE: DHR) is a global science and technology innovator known for its diverse range of products and services in the healthcare, environmental, and industrial sectors. Today, the stock experienced a significant bearish movement amidst recent developments in the market.

Why is Danaher Corporation going down?

DHR stock is down 5.8% on Apr 23, 2026 16:06

• Danaher Corp. settled a class action lawsuit with investors for $173 million, which may have raised concerns about the company's transparency and financial stability, leading to a negative sentiment among investors.
• The stock hitting a 52-week low and analysts revising their price targets downwards could have contributed to the bearish trend, indicating a lack of confidence in the company's current performance and future prospects.
• The downgrade from buy to hold due to weak revenue trends and uncertainties surrounding the Masimo acquisition added further pressure on the stock, highlighting challenges in revenue growth and integration risks.
• The new investment by Juno Financial Group LLC, despite mixed Q1 results and varied analyst reactions, might not have been sufficient to offset the overall negative market sentiment surrounding Danaher Corporation, leading to the bearish movement.

DHR Price Chart

DHR Technical Analysis

DHR News

Danaher Settles Investor Suit Over Projections for $173 Million

Danaher Corp. has agreed to a nearly $173 million class settlement with investors who accused the company of misrepresenting demand for its Covid-19 testing and vaccine equipment as the pandemic subsided. The shareholder leading the lawsuit described the deal as fair and seeks preliminary approval from the U.S. District Court for the District of Columbia. If approved, it would be the largest federal securities fraud class action recovery in the D.C. Circuit since the Private Securities Litigation Reform Act was enacted in 1996.

https://news.bloomberglaw.com/securities-law/danaher-settles-investor-suit-over-projections-for-173-million

Danaher Corporation stock hits 52-week low at $180.00

Danaher Corporation's stock has reached a 52-week low of $180.00, trading at $179.50, reflecting a 5.6% decline over the past year and a 19.4% drop year-to-date. Despite analyst downward revisions, InvestingPro suggests the stock is undervalued. The company recently priced €3 billion in senior notes, and analysts at Morgan Stanley, Stifel, Guggenheim, and Barclays have adjusted their price targets and ratings, indicating ongoing financial and market activities.

https://www.investing.com/news/company-news/danaher-corporation-stock-hits-52week-low-at-18000-93CH-4632847

Danaher Stock: Masimo Deal Adds Long-Term Potential But Near-Term Pressure (NYSE:DHR)

Danaher Corporation has been downgraded from buy to hold due to weak revenue trends and uncertainties surrounding its $9.9 billion Masimo acquisition. While the deal offers long-term growth potential, it introduces near-term debt pressure and integration risks, given the 38% premium paid. Despite strong free cash flow and sector-leading profitability, revenue growth remains stagnant, particularly in its Life Sciences and Diagnostics segments, with capital returns likely limited as debt reduction becomes a priority.

https://seekingalpha.com/article/4893341-danaher-corporation-masimo-deal-adds-long-term-potential-but-near-term-pressure

Juno Financial Group LLC Makes New Investment in Danaher Corporation $DHR

Juno Financial Group LLC has made a new investment in Danaher Corporation (NYSE:DHR), acquiring 9,727 shares valued at approximately $2.227 million in the fourth quarter. This comes as Danaher reported mixed Q1 results with an EPS beat but a revenue miss, leading to varied analyst reactions and a slight stock decline. The company also increased its quarterly dividend and issued new senior notes.

https://www.marketbeat.com/instant-alerts/filing-juno-financial-group-llc-makes-new-investment-in-danaher-corporation-dhr-2026-04-23/

GE HealthCare tests MRI dye as gadolinium alternative

GE HealthCare has initiated a Phase 2/3 clinical trial for mangaciclanol, a manganese-based MRI contrast agent, aiming to provide an alternative to gadolinium-based agents. The investigational agent has received FDA Fast Track designation due to its potential to address concerns regarding gadolinium retention, supply chain security, and environmental impact. Mangaciclanol, if approved, could transform contrast-enhanced MR imaging by offering similar diagnostic performance to existing agents while utilizing a naturally occurring element.

https://www.stocktitan.net/news/GEHC/ge-health-care-announces-first-patient-dosed-in-phase-2-3-lumina-rv8h4bk4erdf.html

Trending Today

Binance Coin ($BNB) Crypto Forecast: Up 3.7% Today

Dogecoin ($DOGE) Crypto Forecast: Up 5.1% Today

Danaher Corporation Price History

13.00.2026 - DHR Stock was down 2.9%

• The decline in Danaher Corporation's stock today, despite positive earnings and growth projections, may be linked to profit-taking by institutional investors and notable reductions in their stake.
• Insider sales by company executives, including SVP Brian W. Ellis and Director Teri List, could also have played a role in the stock's downward trend.
• Market reaction might be influenced by reports of Danaher Corp. co-founder Mitch Rales spearheading a significant funding round for VieCure, diverting attention from the company's core operations and creating uncertainty for investors.
• While Danaher continues to demonstrate strong financial performance and provide optimistic guidance for the future, recent developments in institutional holdings and external investments may have instigated bearish sentiment in the market today.

21.09.2025 - DHR Stock was up 6.3%

• Danaher (DHR) reported Q3 earnings and sales that surpassed expectations, with a significant increase in Life Sciences sales compared to the previous year.
• The strong segment growth and enhanced operating margins contributed to the favorable financial results, indicating effective management and strong market demand for the company's offerings.
• Optimistic assessments and future forecasts from financial analysts prior to the earnings announcement likely influenced investor confidence in Danaher's performance, leading to a positive upward trend in the stock price.
• In summary, the robust Q3 results and promising outlook indicate that Danaher's strategic initiatives and market positioning are well-received by investors, prompting a rise in the stock value.

21.03.2026 - DHR Stock was up 0.2%

• Danaher Corp's bullish movement can be attributed to its strategic positioning as a "pick-and-shovel" provider in the biotech industry, which has garnered investor confidence.
• The increase in institutional stakes, such as a significant investment from Zurcher Kantonalbank Zurich Cantonalbank, signals strong support and belief in Danaher's growth potential.
• Positive Q1 earnings results, beating EPS estimates, and the company's decision to raise its quarterly dividend showcase Danaher's financial strength and performance, further boosting investor optimism.
• The overall positive sentiment surrounding Danaher, coupled with its central role in life sciences infrastructure and potential for stock price appreciation as the biotech market recovers, likely contributed to the bullish market movement observed.

05.00.2026 - DHR Stock was up 0.4%

• Danaher's strategic shift towards higher-margin life sciences and diagnostics is positively impacting investor sentiment and driving the bullish movement.
• The increased stake by Railway Pension Investments Ltd signals confidence in Danaher's future prospects and strong Q3 earnings performance.
• Despite potential risks from early-stage biotech funding weakness, the company's focus on profitable segments and positive analyst ratings are contributing to the stock's upward momentum.
• Overall, the market seems optimistic about Danaher's growth potential and strategic direction, leading to the bullish movement in its stock price.

13.10.2025 - DHR Stock was up 3.4%

• Danaher (DHR) observed a bullish movement today, potentially linked to investors acknowledging its value relative to its competitor Solventum (SOLV).
• Comparative analysis between SOLV and DHR could explain the heightened interest in DHR, resulting in increased buying activity.
• Investors might have identified DHR as the more advantageous stock at present, propelling its price upward.
• The optimistic outlook on DHR's potential value likely played a role in its significant bullish movement today.

02.00.2026 - DHR Stock was up 1.5%

• The bullish movement in Danaher's stock can be attributed to the positive market outlook for bioprocess filtration and single-use bioprocessing products, with recent reports projecting significant market growth driven by increasing demand for biologics and advanced therapies.
• Vanderbilt University acquiring a substantial number of shares in Danaher Corporation further boosted investor confidence, indicating strong institutional interest in the company's performance and potential.
• Danaher's solid Q3 earnings report, surpassing analyst expectations for both earnings per share and revenue, coupled with the announcement of a quarterly dividend, likely contributed to the positive sentiment surrounding the stock.
• The recognition of Danaher as a key player in the bioprocess filtration market alongside competitors like Merck and Sartorius underscores the company's position as a leader in the industry, attracting both investor attention and market confidence.

28.00.2026 - DHR Stock was down 5.1%

• Danaher Corp's Q4 2025 earnings showed a mixed outcome, surpassing expectations in EPS but missing revenue targets. This led to a 1.4% decline in the company's shares.
• The strong performance in the bioprocessing business and positive earnings were overshadowed by the slight revenue miss, which might have sparked concerns among investors.
• Analysts are bullish on Danaher Corp's growth trajectory for 2026, with revenue and EPS projections indicating a return to growth that could potentially restore investor confidence.
• Investor sentiment following the earnings announcement underscored a focus on revenue metrics and a cautious stance on the company's future prospects, contributing to the downward movement in DHR stock.

12.01.2026 - DHR Stock was down 4.2%

• Recent bearish movement in Danaher Corporation's stock could be due to several factors:
• Wealthfront Advisers LLC reduced its stake in DHR by 21.2% in the third quarter, leading to uncertainty among institutional investors and impacting market sentiment negatively.
• Despite strong quarterly earnings and a "Moderate Buy" rating from analysts, exits by notable investors like RFG Advisory LLC and Wallace Weitz may have contributed to the stock's decline.
• The life science tools sector, facing challenges such as constrained biotechnology funding and pricing pressures in China, as noted by the Baron Durable Advantage Fund, could have added to the bearish sentiment surrounding DHR.
• While Danaher Corporation's long-term value and competitive advantages are acknowledged, market reaction may reflect industry challenges and the changing positions of institutional investors in the company.

23.03.2026 - DHR Stock was down 5.8%

• Danaher Corp. settled a class action lawsuit with investors for $173 million, which may have raised concerns about the company's transparency and financial stability, leading to a negative sentiment among investors.
• The stock hitting a 52-week low and analysts revising their price targets downwards could have contributed to the bearish trend, indicating a lack of confidence in the company's current performance and future prospects.
• The downgrade from buy to hold due to weak revenue trends and uncertainties surrounding the Masimo acquisition added further pressure on the stock, highlighting challenges in revenue growth and integration risks.
• The new investment by Juno Financial Group LLC, despite mixed Q1 results and varied analyst reactions, might not have been sufficient to offset the overall negative market sentiment surrounding Danaher Corporation, leading to the bearish movement.

23.03.2026 - DHR Stock was down 6.8%

• A recent new investment in Danaher, along with an increased stake by another entity, indicates continued interest from institutional investors despite the bearish movement.
• The initiation of a Phase 2/3 clinical trial for a potential gadolinium alternative by a well-known healthcare company could have raised concerns about the future competitiveness of Danaher's imaging solutions, impacting investor sentiment.
• Despite strong Q1 earnings and increased EPS guidance, mentions of a revenue miss and price target cuts by analysts likely contributed to the bearish trend in Danaher's stock.
• The pricing of a significant senior notes offering by Danaher to fund an acquisition might have added pressure on the stock price, particularly with the company trading near its 52-week low.

14.03.2026 - DHR Stock was up 5.1%

• Danaher Corporation ($DHR) saw a significant upward trend in trading today.
• The increase in ownership interest from institutional investors like Norris Perne & French LLP MI and JM2 Capital Inc. reflects a positive outlook on the company's performance.
• Danaher reported robust Q4 earnings, surpassing expectations with $2.23 EPS and $6.84 billion in revenue, resulting in a favorable market response.
• The decision to raise the quarterly dividend to $0.40 also played a role in the upward movement, attracting more investors. The company continues to hold a "Moderate Buy" consensus rating with an average target price of $249.60.

22.03.2026 - DHR Stock was down 5.1%

• Despite surpassing first-quarter earnings expectations and increasing full-year earnings forecast, Danaher Corp (DHR) stock fell by 3.40% due to a revenue miss, flat organic growth, and margin compression, resulting in downward adjustments in price targets.
• Weaknesses in the Diagnostics segment and concerns regarding the planned Masimo acquisition contributed to market caution and negative sentiment among investors, overshadowing positive aspects of the earnings report.
• The bearish movement may also be influenced by insider trading data indicating significant sales by executives, further fueling apprehension in the market regarding the company's near-term performance and growth prospects.
• Analysts' reduced price targets for Danaher (DHR) stock, while maintaining a "buy" rating, suggest a cautious outlook that could have added to the downward pressure on the stock price.